Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context

References

• SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
   PubMed Web of Science ®Google Scholar
• Enbrel^® (etanercept) [package insert]Thousand Oaks, CAAmgen Inc2013
   Google Scholar
• Humira^® (adalimumab) [package insert]North Chicago, ILAbbVie Inc2014
   Google Scholar
• Remicade^® (infliximab) [package insert]Horsham, PAJanssen Biotech Inc2013
   Google Scholar
• Orencia^® (abatacept) [package insert]Princeton, NJBristol-Myers Squibb Co2013
   Google Scholar
• HelmickCGFelsonDTLawrenceRCEstimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part IArthritis Rheum2008581152518163481
   PubMed Web of Science ®Google Scholar
• About PCMA [webpage on the Internet]Washington, DCPharmaceutical Care Management Association (PCMA) Available from: http://www.pcmanet.org/about-pcma/about-pcmaAccessed February 26, 2015
   Google Scholar
• LeungMYHalpernMTWestNDPharmaceutical technology assessment: perspectives from payersJ Manag Care Pharm201218325626422468734
   PubMed Web of Science ®Google Scholar
• Drug therapy for rheumatoid arthritis in adults: an update [webpage on the Internet]Rockville, MDAgency for Healthcare Research and Quality2013 Available from: http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1795Accessed February 26, 2015
   Google Scholar
• GreenbergJDReedGDecktorDA comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registryAnn Rheum Dis20127171134114222294625
   PubMed Web of Science ®Google Scholar
• SinghJAChristensenRWellsGAA network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overviewCMAJ20091811178779619884297
   PubMed Web of Science ®Google Scholar
• WuNLeeYCShahNHarrisonDJCost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort studyClin Ther20143681231124125062652
   PubMed Web of Science ®Google Scholar
• BlumeSWFoxKMJosephGChuangCCThomasJGandraSRTumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management settingAdv Ther201330551752723740359
   PubMed Web of Science ®Google Scholar
• CurtisJRBaddleyJWYangSDerivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritisArthritis Res Ther2011135R15521933396
   PubMed Web of Science ®Google Scholar
• CurtisJRChastekBBeckerLFurther evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims dataArthritis Res Ther201315240423472737
   PubMed Web of Science ®Google Scholar
• CurtisJRChastekBBeckerLCost and effectiveness of biologics for rheumatoid arthritis in a commercially insured populationJ Manag Care Spec Pharm201521431832925803765
   PubMed Web of Science ®Google Scholar
• CurtisJRSchabertVFHarrisonDJEstimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claimsClin Ther2014367996100425012729
   PubMed Web of Science ®Google Scholar
• CurtisJRSchabertVFYeawJUse of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritisJ Med Econ201417855556624754646
   PubMedGoogle Scholar
• SikkaRXiaFAubertREEstimating medication persistency using administrative claims dataAm J Manag Care200511744945716044982
   PubMed Web of Science ®Google Scholar
• BonafedeMMGandraSRFoxKMWilsonKLTumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationJ Med Econ201215463564322332705
   PubMedGoogle Scholar
• FisherMDWatsonCFoxKMChenYWGandraSRDosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationCurr Med Res Opin201329556156823489410
   PubMed Web of Science ®Google Scholar
• GilbertTDJrSmithDOllendorfDAPatterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord2004513615485582
   PubMed Web of Science ®Google Scholar
• HarrisonDJHuangXGlobeDDosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritisAm J Health Syst Pharm201067151281128720651319
   PubMed Web of Science ®Google Scholar
• HuangXGuNYFoxKMHarrisonDJGlobeDComparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practiceCurr Med Res Opin20102671637164520429830
   PubMed Web of Science ®Google Scholar
• JoyceATGandraSRFoxKMSmithTWPillMWNational and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plansJ Med Econ201417111024131136
   PubMedGoogle Scholar
• SchabertVFBruceBFerrufinoCFDisability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness studyCurr Med Res Opin201228456958022236091
   PubMed Web of Science ®Google Scholar
• CannonGWDuVallSLHaroldsenCLPersistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritisJ Rheumatol201441101935194325128516
   PubMed Web of Science ®Google Scholar
• AndersonJCaplanLYazdanyJRheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practiceArthritis Care Res (Hoboken)201264564064722473918
   PubMed Web of Science ®Google Scholar